State Food and Drug Administration: China's domestic extracorporeal membrane oxygenation therapy (ECMO) products have been approved for marketing

According to the State Food and Drug Administration, according to the needs of epidemic prevention and control work, in order to ensure the treatment needs of severe patients with novel coronavirus pneumonia, on January 4, 2023, the State Food and Drug Administration approved the registration application of Shenzhen Hannuo Medical Technology Co.
, Ltd.
in vitro cardiopulmonary support auxiliary equipment and disposable membrane oxygenator package after review, which are used together for adult patients
with acute respiratory failure or acute cardiopulmonary failure, other treatments that are difficult to control and have a foreseeable risk of continuous deterioration or death 。 As the first domestic ECMO equipment and consumables package, the above products have independent intellectual property rights, and the performance indicators basically reach the international level of similar products
.